[1] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020 Feb 28, DOI: 10.1056/NEJMoa2002032.
[2] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020 Feb 15;395(10223):497-506.
[3] Wei-Jie Guan, Zheng-Yi Ni, Yu Hu, Wen-Hua Liang, Chun-Quan Ou, Jian-xing He, Lei Liu, Hong Shan, Chun-Liang Lei, David SC Hui, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020.02.06.20020974; DOI: https://doi.org/10.1101/2020.02.06.20020974.
[4] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020 Mar 27. DOI: 10.1172/JCI137244.
[5] Sarawar, S. R., M. Sangster, R. L. Coffman, P. C. Doherty. Administration of anti-IFN-gamma antibody to beta 2-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J. Immunol. 1994. 153: 1246–1253.
[6] Topham, D. J., R. A. Tripp, S. R. Sarawar, M. Y. Sangster, P. C. Doherty. Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II2/2respiratory epithelium. J. Virol. 1996.70: 1288–1291.
[7] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513
[8] Haipeng Zhang, Ti Wu. CD4+T, CD8+T counts and severe COVID-19: A meta-analysis. J Infect. 2020 Sep;81(3): e82-e84.
[9] Zeming Liu, Wei Long, Mengqi Tu. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect. 2020 Aug;81(2):318-356.
[10] J M Urra, C M Cabrera, L Porras, et al. Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clin Immunol. 2020 Aug; 217: 108486.
[11] Milos Jesenak, Miroslava Brndiarova, Ingrid Urbancikova, et al. Immune Parameters and COVID-19 Infection – Associations with Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol. 2020 Jun 30;10: 364.
[12] Hong-Yi Zheng, Mi Zhang, Cui-Xian Yang, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020 May;17(5):541-543.
[13] Diane E Griffin. Are T cells helpful for COVID-19: the relationship between response and risk. J Clin Invest. 2020 Sep 25;142081.
[14] Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020 Jun;20(6):363-374.
[15] David Schub, Verena Klemis, Sophie Schneitler, et al. High levels of SARS-CoV-2 specific T-cells with restricted functionality in severe course of COVID-19. JCI Insight. 2020 Sep 16;142167.
[16] Diao B, Wang CH, Tan YJ, Chen XW, Liu Y, Ning LF, Chen L, Li M, Liu YP, Wang G et al. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). MedRxiv, 2020.02.18.20024364; DOI: https://doi.org/10.1101/2020.02.18.20024364.
[17] Menglu Gao, Yili Liu, Mingquan Guo. Regulatory CD4+ and CD8+ T cells are negatively correlated with CD4+ /CD8+ T cell ratios in patients acutely infected with SARS-CoV-2. J Leukoc Biol. 2020 Sep 15. DOI: 10.1002/JLB.5COVA0720-421RR.
[18] Luka Nicin, Wesley Tyler Abplanalp, Hannah Mellentin, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J. 2020 May 14;41(19):1804-1806.
[19] Kamal Kant Sahu, Ahmad Daniyal Siddiqui. From Hematologist's desk: The effect of COVID-19 on the blood system. Am J Hematol. 2020 Aug;95(8): E213-E215.
[20] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Mar 30. DOI: 10.1016/S1473-3099(20)30243-7.
[21] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. DOI: 10.1001/jama.2020.1585.
[22] Monica Fung, Jennifer M Babik. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2020 Jun 27; ciaa863.